The Food and Drug Administration says it has approved a new form of a best-selling breast cancer drug that targets tumor cells while sparing healthy ones.
The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy and a third chemical linking the medicines together. The chemical keeps the drugs intact until they bind to a cancer cell, where the double-shot of medication is released.
The FDA approved the new treatment for about 20 percent of breast cancer patients who have a particular form of the disease. These patients have tumors that overproduce a protein known as HER-2.
The approval will help Roche build on the success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year.